The Capability of Tc-99m MIBI Total Body Scan Compared with I-131 Total Body Scan for Detecting Recurrence and Metastasis in Differentiated Thyroid Carcinoma

Authors

  • Pichanun Pothisoonthorn, M.D. Nuclear medicine unit, Lampang Cancer Hospital

Keywords:

Differentiated thyroid carcinoma, I-131, Tc-99m MIBI, Scan

Abstract

Background: I-131 is the main radiopharmaceutical for differentiated thyroid carcinoma. However, Tc-99m MIBI is also an alternative agent, which uses to detect recurrence or metastasis in several malignancies, including differentiated thyroid carcinoma.Objective: This study aimed to evaluate the capability of Tc-99m MIBI total body scan to detect recurrence and metastasis in patients with differentiated thyroid carcinoma at Lampang Cancer Hospital, compared to the scan with I-131.Method: A retrospective study performed in the patients with differentiated thyroid carcinoma status from database post total thyroidectomy from the other hospitals who came for I-131 treatment at Lampang Cancer Hospital from July 1st, 2012 to June 30th, 2019. The patients received the total body scan with I-131 and Tc-99m MIBI to detect recurrence and metastasis. Then, the concordance tested with the Kappa test and identified the scanning method with the receiver operating characteristic (ROC).Result: The 395 patients of differentiated thyroid carcinoma received the I-131 and Tc-99m MIBI total body scans to detect recurrence and metastasis. Tc-99m MIBI whole body scan had 77.98% sensitivity, which is higher sensitivity than the I-131 scan, which had 77.52% sensitivity. The sensitivity of the Tc-99m MIBI scan for identification of recurrence, regional node metastasis, and distant metastasis was 63.49%, 79.35%, and 90.48%, respectively. The sensitivity of I-131 scintigraphy for detecting recurrence, regional node metastasis, and distant metastasis was 65.08%, 80.43%, and 85.71%, respectively. Moreover, Tc-99m MIBI total body scan had concordance with the I-131 scan.Conclusion: Tc-99m MIBI scan can detect recurrence and metastasis higher than the scan with I-131, especially distant metastasis. This modality can be the alternative scintigraphy for follow-up after treatment.

Downloads

Download data is not yet available.

References

Haugen BR, Alexande EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guideline for adult patients with thyroid nodule and differentiated thyroid carcinoma.Thyroid. 2016: 1-92

Ziessman HA, O’Malley JP, Thrall JH. editors. The requistites nuclear medicine. Mosby Elsevier 2006;1:3-20,264-5.

Ell PJ, Gambhir SS. editors. Nuclear medicine in clinical diagnosis and treatment. Churchill Liverstone 2004;1:3-10, 145-58

Hospital based cancer registry Lampang cancer hospital 2017.LPCH cancer registry publication. 2017; 36:6-7

Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated thyroid cancer - treatment state of the art. Int J Mol Sci 2017;18:1292.

Dabiri SH. 99MTc-MIBI scintigraphy versus 131I whole body scan in follow-up of patient with differentiated thyroid cancer. J Med Sci 2006;6:806-11.

Sriprapaporn J, Toopmongkol C, Satayaban B, Chantamoon N.Technetium-99m methoxyisobutylisonitrile imaging in follow-up of differentiated thyroid carcinoma. Ann Acad Med Singap 2002;31:195-8.

Miyamoto S, Kasagi K, Misaki T, Alam MS, Konishi J. Evaluation of technitium-99m - MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J Nucl Med 1997;38: 352-6.

Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P. Thyroglobulin and low – dose iodine -131 and technitium-99m-tetrofosmin whole body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1998;39:870-5.

Pan X, Duan D, Zhu Y, Pang H, Lv Z. Value of 99m-Tcmethoxybutylisonitrile imaging after first time large dose 131I therapy in treating differentiated thyroid cancer. Dove Press J 2016; 9:723-30.

Rubello D, Mazzarotto R, Casara D. The role of technitium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow - up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 2000; 27:431-40.

Almeida-Filho P, Ravizzini GC, Almeida C, Borges- Neto S.Whole body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma. Clin Nucl Med 2000; 25:443-6.

Hsu CH, Liu FY, Yen RF, Kao CH. Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patient with elevated serum thyroglobulin level but negative I-131 whole body scan.Endocr Res 2003; 29:9-15.

Published

03-09-2021

How to Cite

1.
Pothisoonthorn พ. The Capability of Tc-99m MIBI Total Body Scan Compared with I-131 Total Body Scan for Detecting Recurrence and Metastasis in Differentiated Thyroid Carcinoma. j dept med ser [Internet]. 2021 Sep. 3 [cited 2022 Aug. 9];46(2):39-47. Available from: https://he02.tci-thaijo.org/index.php/JDMS/article/view/253527

Issue

Section

Original Article